Mangoceuticals, Inc. in brief
Mangoceuticals, Inc. is a listed company, based in Dallas, Texas, USA. Its market value was $6 M on 20 October 2026, which makes it the 26,613th largest listed company in the world and the 4,373rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $21 M. Its shares trade under the symbol MGRX (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Mangoceuticals, Inc.
—Material Agreements—Master Services Agreement with Epiq Scripts”, we have entered into an agreement with Epiq Scripts, a related party, 52% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide us compounding and other pharmacy services.
Our operations are subject to extensive government regulation, from the entry into agreements with physicians or groups of physicians to provide telehealth services to our potential customers, to the marketing and promotion of our products, the creation of our products, and the sale of our products through licensed pharmacists.
From the company's annual report filed with the US SEC: read the report
Mangoceuticals, Inc. timeline
- 2022
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Mangoceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 20.1×
- Price / book
- 0.4×
- Free cash flow yield
- -112.5%
- Net margin (TTM)
- -3554.8%
- Operating margin
- -3919.6%
- Return on equity
- -72.5%
- Liabilities / assets
- 5.5%
- Revenue growth
- -25.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -25.8% | $-18M | $-21M | -4487.0% |
| Dec 2024 | $1M | -15.1% | $-8M | $-9M | -1404.8% |
| Dec 2023 | $1M | — | $-9M | $-9M | -1261.6% |
| Dec 2022 | — | — | $-2M | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-6M | — | — | $-2.17 | — |
| Dec 2024 | $-5M | — | — | $-4.80 | — |
| Dec 2023 | $-7M | $0M | $-7M | $-8.58 | — |
| Dec 2022 | $-1M | $0M | $-1M | $-0.19 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (-12.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 17, 2026DEF 14AProxy statement
- Nov 16, 202610-QQuarterly report · period to Sep 2026
- Nov 13, 20268-KCurrent reportBylaws amended · Shareholder vote
- Nov 6, 20268-KCurrent reportShareholder vote · Other events
- Oct 9, 20268-KCurrent reportMaterial agreement
- Oct 1, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Unregistered share sale · Regulation FD disclosure
- Aug 21, 20268-KCurrent reportAgreement ended
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportOther events
- Jul 30, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Bylaws amended · Regulation FD disclosure
- Jul 2, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- May 19, 202610-QQuarterly report · period to Mar 2026
Official filings of Mangoceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-18 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $16 M
- Total liabilities
- $1 M
- Total equity
- $15 M
As of December-2025
Top 19 institutional investors in Mangoceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 689,270 | +533,027 (+341.15%) | 3.20% | $0 M | Nov 6, 2026 |
| 2 | Jane Street Group, LLC | 214,629 | New | 1.00% | $0 M | Nov 12, 2026 |
| 3 | Citadel Advisors LLC | 189,004 | -149,960 (-44.24%) | 0.88% | $0 M | Nov 16, 2026 |
| 4 | Ikarian Capital, LLC | 138,146 | 0 (0.00%) | 0.64% | $0 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 123,041 | 0 (0.00%) | 0.57% | $0 M | Nov 13, 2026 |
| 6 | Morgan Stanley | 70,600 | +69,600 (+6960.00%) | 0.33% | $0 M | Nov 13, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 57,163 | 0 (0.00%) | 0.27% | $0 M | Nov 13, 2026 |
| 8 | Boothbay Fund Management, LLC | 38,441 | 0 (0.00%) | 0.18% | $0 M | Nov 16, 2026 |
| 9 | Northern Trust Corp | 37,579 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 10 | Ackerman Capital Advisors, LLC | 34,500 | 0 (0.00%) | 0.16% | $0 M | Oct 30, 2026 |
| 11 | StoneX Group Inc. | 24,099 | New | 0.11% | $0 M | Nov 3, 2026 |
| 12 | XTX Topco Ltd | 22,180 | -164,076 (-88.09%) | 0.10% | $0 M | Nov 16, 2026 |
| 13 | ACT Advisors, LLC. | 12,314 | -14,549 (-54.16%) | 0.06% | $0 M | Oct 15, 2026 |
| 14 | Csenge Advisory Group | 10,000 | 0 (0.00%) | 0.05% | $0 M | Nov 4, 2026 |
| 15 | Fortitude Family Office, LLC | 3,074 | +1,731 (+128.89%) | 0.01% | $0 M | Oct 14, 2026 |
| 16 | Ameriflex Group, Inc. | 2,885 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 17 | Tower Research Capital LLC (TRC) | 763 | -20 (-2.55%) | 0.00% | $0 M | Nov 16, 2026 |
| 18 | Robinhood Markets, Inc. | 121 | — | 0.00% | $0 M | Nov 18, 2026 |
| 19 | Northwestern Mutual Wealth Management Co | 100 | New | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Mangoceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 109,105 | $0 M | 0.51% | <0.01% | +37% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 123,041 | $0 M | 0.57% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 14,438 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 12,606 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 453 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
As of Jun 30, 2026
Insider trading at Mangoceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jacob D. CohenChief Executive Officer, Director, 10% owner | Gift | -2.00 M | — | — | 0 | Form 4 |
| filed | Jacob D. CohenChief Executive Officer, Director, 10% owner | Gift | +2.00 M | — | — | 3.31 M | Form 4 |
| filed | Alex P. HamiltonDirector | Grant or award | +100,000 | — | — | 101,667 | Form 4 |
| filed | Eugene M. JohnstonCFO | Grant or award | +100,000 | — | — | 220,000 | Form 4 |
| filed | Jacob D. CohenChief Executive Officer, Director, 10% owner | Grant or award | +2.00 M | — | — | 2.00 M | Form 4 |
| filed | Eugene M. JohnstonCFO | Sell | -3,333 | $1.170 | $4 K | 120,000 | Form 4 |
| filed | Eugene M. JohnstonCFO | Sell | -5,000 | $1.200 | $6 K | 123,333 | Form 4 |
| filed | Eugene M. JohnstonCFO | Sell | -10,000 | $1.130 | $11 K | 128,333 | Form 4 |
Markets and events: Mangoceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-07-31 14:30 UTC, code LUDP, resumed 14:35 UTC
- 2026-07-31 14:22 UTC, code LUDP, resumed 14:27 UTC
- 2026-07-31 14:16 UTC, code LUDP, resumed 14:21 UTC
- 2025-03-25 13:43 UTC, code LUDP, resumed 13:53 UTC
- 2025-03-25 13:34 UTC, code LUDP, resumed 13:39 UTC
Fails to deliver
- : 80,014 shares at $0.28
- : 11,324 shares at $0.45
- : 23,395 shares at $0.48
- : 33,439 shares at $0.43
- : 32,059 shares at $0.44
Mangoceuticals, Inc. scorecard#
Passes 1 of the 10 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation0 of 3
Growth0 of 1
Profitability0 of 2
Financial health1 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Mangoceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 456 | 616 | 731 | 8.9 | |
| Cost of revenue | 54 | 93 | 155 | 4.1 | |
| Gross profit | 250 | 380 | 432 | 4.9 | |
| General and administrative | 3,756 | 3,001 | 3,319 | 1,644 | |
| Operating expenses | 18,283 | 8,352 | 9,650 | 1,996 | |
| Operating income | −18,032 | −7,972 | −9,219 | −1,992 | |
| Interest expense and finance costs | 104 | 14 | −6.5 | 6.5 | |
| Other non-operating income (expense) | −2,611 | −735 | 6.5 | −6.5 | |
| Income before tax | −20,643 | −8,707 | −9,212 | −1,998 | |
| Net income including minority interests | −20,643 | −8,707 | −9,212 | — | |
| Minority interests' share of net income | −0.5 | −1.1 | — | — | |
| Net income attributable to shareholders | −20,643 | −8,706 | −9,212 | −1,998 | |
| Earnings per share, basic | -2.17 | -4.80r | -8.58r | -0.19 | |
| Earnings per share, diluted | -2.17 | -4.80r | -8.58r | -0.19 | |
| Shares, weighted average (basic) | 10 | 2.0 | 1.1r | 11 | |
| Shares, weighted average (diluted) | 10 | 2.0 | 1.1r | 11 | |
| Balance sheet | |||||
| Cash and cash equivalents | 1,486 | 59 | 739 | 683r | |
| Inventory | — | — | 19 | — | |
| Current assets | 1,547 | 76 | 835r | 695 | |
| Property, plant and equipment | 1.8 | 2.8 | 96 | 117 | |
| Right-of-use (leased) assets | 308 | 59 | 119 | 174 | |
| Other intangible assets | 14,232 | 15,233 | — | — | |
| Non-current assets | 14,542 | 15,295 | 215 | — | |
| Total assets | 16,090 | 15,371 | 1,051 | 1,003 | |
| Accounts payable | 417 | 838 | 141 | 34 | |
| Current liabilities | 891 | 1,425 | 211 | 261 | |
| Lease liabilities (non-current) | — | — | 65 | 129 | |
| Non-current liabilities | — | — | 65 | 129 | |
| Total liabilities | 891 | 1,425 | 276 | 389 | |
| Retained earnings | −40,647 | −20,004r | −11,228 | −2,016 | |
| Shareholders' equity | 15,201 | 13,946 | 775 | 614 | |
| Minority interests | −1.5 | −1.1 | — | — | |
| Total equity | 15,199 | 13,945 | 775 | 614r | |
| Total liabilities and equity | 16,090 | 15,371 | 1,051 | 1,003 | |
| Shares outstanding | 16 | 3.2 | 1.4r | 13 | |
| Cash-flow statement | |||||
| Depreciation and amortization | — | 9.9 | 25 | — | |
| Share-based compensation | 1,168 | 249 | 624 | 234 | |
| Cash from operating activities | −5,850 | −4,864 | −6,997 | −1,347 | |
| Capital expenditure | — | — | −3.5 | −43 | |
| Cash from investing activities | — | 65 | −3.5 | −43 | |
| Shares issued | 4,625 | 1,328 | 6,200 | 2,000 | |
| Cash from financing activities | 7,271 | 4,128 | 7,057 | 2,050 | |
| Change in cash | — | — | 56 | 660 | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
Events at Mangoceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Acquisition or sale completed 3 · Directors and officers 5 · Material agreement 14 · Agreement ended 4 · New debt 3 · Unregistered share sale 10 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Acquisition or sale completedMaterial agreementUnregistered share sale | 8-K | |
| Agreement ended | 8-K | |
| Directors and officersMaterial agreementBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersMaterial agreementAgreement endedNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Acquisition or sale completedMaterial agreementAgreement ended | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K |
As of Nov 13, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2022 | $2 M | No. 1 | Under $2 million | 19 | equity, options | SEC |
Questions, comparisons and similar companies#
How current the figures are
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mangoceuticals, Inc.? Verify and update this profile — free
Show Mangoceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.